# Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

> **NCT05509699** · PHASE2 · COMPLETED · sponsor: **Hutchison Medipharma Limited** · enrollment: 21 (actual)

## Conditions studied

- Extensive-Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Surufatinib
- **DRUG:** Anti-PD-1/L1

## Key facts

- **NCT ID:** NCT05509699
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-27
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05509699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05509699, "Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05509699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*